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Introduction
High levels of cell-associated HIV-1 RNA can be observed in
peripheral blood of patients with undetectable plasma viremia
during combination antiretroviral therapy (cART) [1–4]. The
various HIV-1 RNA and DNA species that are present during the
viral life cycle can serve as biomarkers for basal transcription in
viral reservoirs with different properties [5,6]. Gaining a quanti-
tative understanding of the development and turnover of HIV-1-
infected subpopulations and viral latency is of particular interest in
light of recent efforts in viral eradication strategies [7–10].
Highly sensitive assays for HIV-1 plasma RNA in patients on
cART usually provide bulk measurements of viral activity and
cannot distinguish between different infected subpopulations [11].
In contrast, the study by Fischer et al. [12] combined highly
sensitive PCR assays for unspliced (UsRNA) and multiply spliced
(MsRNA-tatrev and MsRNA-nef) HIV-1 RNA species with
limiting dilution endpoint analysis of peripheral blood mononu-
clear cells (PBMCs). In addition to intracellular RNA transcripts,
extracellular virion-enclosed HIV-1 RNA that provides a marker
for cells releasing virus particles was also measured. The study
identified four distinct viral transcriptional classes: two overlapping
cell classes of high viral transcriptional activity, representative of a
virus producing phenotype; and two cell classes that express HIV-
1 RNA at low and intermediate levels that match definitions of
viral latency [12,13].
Analyzing the decay kinetics of plasma viral load in HIV-1-
infected patients on cART using mathematical models has resulted
in a detailed understanding of viral replication dynamics in vivo
[14–16]. The plasma viral load typically exhibits three exponential
phases during the first year after start of cART (Figure 1). Due to
the rapid turnover of free virus in blood [17], the viral decay
phases are thought to reflect the contribution of different HIV-1-
infected cell populations on viral production. The first phase with
a half-life of 1 to 2 days is attributed to the loss of activated, virus-
producing cells [18,19]. The second phase exhibits a half-life of 1
to 4 weeks and is considered to reflect the loss of so-called
persistently infected cells with a lower state of activation [20,21].
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The third phase decay has a long half-live of 39 weeks suggesting
that latently infected cells are a primary candidate for this cellular
compartment [22,23], although slow release of virus from the
follicular dendritic cell network is another possibility [24].
Although not shown in Figure 1, in many patients, after the third
phase a final low steady state level of plasma viremia is attained,
that has been called a fourth phase [22]. This phase has also been
attributed to release of virus from activated latently infected cells
[22]. Other mathematical models have been developed that
stratify the infected cells into additional subpopulations such as
non-productively infected cells during the intracellular eclipse
phase [25] and defectively infected cells [26]. Nevertheless, most
studies to date are focused on the analysis of viral load and only
indirectly allow inferring the kinetics of cellular subpopulations.
Few studies have attempted to characterize the concentration of
virus and several infected subpopulations based on data simulta-
neously [26]. Fitting mathematical models to multiple quantities of
viral replication would result in refined parameter estimates for
describing the generation and maintenance of latently infected
cells.
In this study, we developed a mathematical model that describes
the dynamics of different transcriptionally active subclasses of
HIV-1-infected cells and the viral load in peripheral blood. The
model was fitted to previously published data from five chronically
HIV-1-infected patients starting cART [12]. This allowed us to
estimate critical parameters of the within-host dynamics of HIV-1
and the turnover of various subpopulations of infected cells.
Finally, we simulated the development of the latently infected cell
pool during acute infection, providing useful information for viral
eradication strategies.
Results
We first devised a detailed model of the within-host dynamics
of HIV-1 that is based on the observations of different subclasses
of HIV-1-infected cells in the study by Fischer et al. [12]. The five
subclasses are HIV-1 DNAz, low, medium and high HIV-1
RNA expressing and cells that have virion-enclosed HIV-1 RNA
associated with them (also see Methods). These subclasses show
distinct decay dynamics in patients on cART (Figure 2). The slow
decay of the subclass of PBMCs that contains proviral DNA
(DNAz) indicates that this cell population primarily contributes
to the third phase decay and likely consists of defectively or
latently infected cells to a large extent. The subclass of cells
exhibiting UsRNA only (Low) decays slowly and most likely
consists mainly of latently infected cells with low basal transcrip-
tion of HIV-1. The cells with medium transcriptional activity
(Mid) appear to contribute to the second and the third phase viral
decay, which is characteristic of persistently and latently infected
cells. The early drop in PBMCs with a higher transcriptional
activity (High), which is more pronounced compared to cells with
a low and medium transcriptional activity, that is followed by a
slower loss of cells is reminiscent of activated, virus-producing
and persistently infected cells. Finally, the PBMCs that have
extracellular virion-enclosed HIV-1 RNA associated with them
(Extra) show a very rapid loss before reaching the limit of
detection. This is expected as they should represent the short-
lived population of virus-producing cells [4] that contribute to the
first phase of viral decay.
The different subclasses of HIV-1-infected cells clearly overlap
and are representative of heterogeneous cell populations. Further-
more, the life cycle of HIV-1 from infection of a cell to the release
of virus particles can be divided into cell populations with different
transcriptional activity [27]. We took both of these important
characteristics into account in our model that consists of 12
subpopulations of cells that can be stratified according to their
HIV-1 DNA and RNA content (Figure 3 and Methods). In this
model, we defined persistently infected cells (M1 and M2) as long-
lived cells that can produce viral particles. Latently infected cells
(L1 and L2) were assumed to transcribe HIV-1 RNA at low or
intermediate levels [12,13]. Infected cells that are HIV-1 DNA
positive, but HIV-1 RNA negative, were assumed to remain
transcriptionally silent during the observation period and consid-
ered as defectively infected cells (D).
Figure 1. Three-phase decay of HIV-1 after start of cART. The
black line shows a typical decay profile of plasma viral load during the
first year of cART. Typical half-lives of the first (blue dashed line), second
(red dotted line) and third phase (green dash-dotted line) are 1.5 days, 4
weeks and 39 weeks, respectively [22].
doi:10.1371/journal.pcbi.1003871.g001
Author Summary
Gaining a quantitative understanding of the development
and turnover of different HIV-1-infected subpopulations of
cells is crucial to improve the outcome of patients on
combination antiretroviral therapy (cART). The population
of latently infected cells is of particular interest as they
represent the major barrier to a cure of HIV-1 infection. We
developed a mathematical model that describes the
dynamics of different transcriptionally active subclasses
of HIV-1-infected cells and the viral load in peripheral
blood. The model was fitted to previously published data
from five chronically HIV-1-infected patients starting cART.
This allowed us to estimate critical parameters of the
within-host dynamics of HIV-1, such as the the number of
virions produced by a single infected cell. The model
further allowed investigation of HIV-1 dynamics during the
acute phase. Computer simulations illustrate that latently
infected cells become rapidly established during the first
months of acute infection and continue to increase slowly
during the first years of chronic infection. This illustrates
the opportunity for strategies that aim to eradicate the
virus during early cART as the pool of HIV-1 infected cells is
substantially smaller during acute infection than during
chronic infection.
Quantifying the Turnover of HIV-1-Infected Cells
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Fitting the mathematical model to the data from five HIV-1-
infected patients resulted in a good description of the viral and
cellular decay kinetics during cART (Figure 4 and Text S1). The
individual dynamics of each subpopulation of cells are shown
separately (Figure 5). The model clearly describes more pro-
nounced decay dynamics in infected cells with increasing transcrip-
tional activity. Table 1 provides a summary of the geometric means
as well as the ranges of the best fit parameter estimates that describe
the virus dynamics in each of the five patients. We found that 1.1%
(0.2%–7.0%) of all CD4z T cells can be target cells for infection
with HIV-1. We also obtained estimates for the average lifespans of
target cells (61 days, range: 11–528 days) and latently infected cells
(33 years, range: 168 days–505 years). While others have estimated
the average half-life of latently infected cells to be 6.3 months [28]
and 44 months [29], our estimates are less precise due to the much
shorter follow-up period after start of cART. However, the
estimated activation rate of latently infected cells (2:7|10{3 d{1,
range: 5:3|10{5{1:5|10{1 d{1) that also influences the slope
of the third phase decay in plasma HIV-1 RNA is consistent with
previous findings [30].
The parameters fD, fL and fM denote the fractions of cells
that end up in a particular subpopulation in a sequential process
during the intracellular eclipse phase. From this, we can
calculate the average proportion of newly infected cells that
become a certain cell type (Text S1). In contrast to another
study [26], we find that only 63.4% (0.2%–7.0%) of infected
cells become activated, virus-producing cells (I6). A substantial
fraction of infected target cells results in defectively (14.0%) and
persistently infected cells (21.2%). The proportion of infected
cells that become latently infected or die before ending up in
one of the subpopulations is small (0.3% and 1.1%, respective-
ly). Note that after activation, latently infected cells can then
either become persistently infected or activated, virus-producing
cells by moving through cell class I4. Transcriptional bursts that
increase the level of viral RNA transcription occur on average
every 12.7 days (1=s2, range: 3.5–165.2 days) and 9.7 days
(1=k2, range: 1.5–37.0 days) in latently and persistently infected
cells, assuming that bursts last for one day on average
(s1~k1~1 d
{1). The total number of virus particles produced
by a cell during its lifetime, the viral burst size, was estimated at
219000 virions per cell (range: 39500–2409000 virions per cell).
Note that we assumed that persistently infected cells in an
elevated transcriptional state (M2) produce viral particles at the
same rate as activated, virus-producing cells. However, the
duration of virus release is shorter in persistently infected cells as
they can revert to a lower transcriptional state (M1). The
majority of virus particles is produced by activated, virus-
producing cells I6 (68.3%, range: 5.6%–98.1%) with the
remaining proportion being produced by persistently infected
cells M2. The high viral burst size suggests that the total number
of virus-producing cells in peripheral blood must be small and
we indeed found an average of only 25.7 cells ml{1 (range: 7.8–
143.1 cells ml{1) in the model during the chronic phase of
infection.
The parameters were estimated by fitting the virus dynamics
model to data of patients chronically infected with HIV-1.
Although there are mathematical models that describe acute
and chronic HIV infection together [31,32], the virus dynamics
during acute infection could differ significantly due to different
parameter values and even model structures. Nevertheless, our
model can still be used to simulate the virus dynamics during the
acute phase and compare the results to experimental and
clinical data. We used the average of the estimated parameters
to simulate early infection with HIV-1 from a small viral
Figure 2. Decay kinetics of subclasses of HIV-1-infected cells during cART. The five subclasses of PBMCs are: DNAz (containing HIV-1 DNA,
black circles), Low (containing solely HIV-1 UsRNA, red diamonds), Mid (containing only HIV-1 MsRNA-tatrev or MsRNA-nef, green crosses), High
(containing elevated levels of both HIV-1 MsRNA-tatrev and MsRNA-nef, blue triangles) and Extra (carrying virion-enclosed HIV-1 RNA, chocolate
squares). Thick lines and symbols represent the geometric means of the five patients from the study by Fischer et al. [12]. Thin transparent lines for
each color represent the original data for each subclass of cells of each individual patient. The dashed line represents the limit of detection that was
set at 50% of the lowest measured cell count. Measurements below this threshold were assumed to be at 50% of the detection limit to include them
in the mean.
doi:10.1371/journal.pcbi.1003871.g002
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inoculum in a hypothetical patient. We set V (0)~1 copy per ml
and assumed that the target cells are at steady-state
(T(0)~l=dT ). The rapid rise of plasma HIV-1 RNA during
the first weeks of infection is followed by the chronic phase at
which the virus concentration reaches its set-point level
(Figure 6). The total pool of latently infected cells (L1zL2) show
somewhat different dynamics during acute HIV-1 infection. A
very rapid expansion of latent cells during the viral growth phase
is followed by a slower increase into the chronic phase of
infection. From the time of peak viremia (22 days) to the chronic
phase (1000 days), the latently infected cell pool expands 14.3-
fold from 9.8 to 140.4 cells per ml. The expansion of the total
number of HIV-1 DNA positive cells from the acute (1813 cells
per ml) to the chronic phase (7608 cells per ml) is smaller (4.2-
fold). This is consistent with the 3.8-fold difference in the number
of HIV-1 DNA copies that were measured in patients that
initiated cART during the acute and chronic phase from another
study [33, and see Text S1]. The time after infection at which
latently infected and HIV-1 DNA positive cells reach 50% of
their chronic level is 441 and 451 days, respectively. Altogether,
this illustrates the opportunity for eradication strategies during
early cART interventions as the pool of HIV-1 infected cells
seems to be substantially smaller during acute infection than
during chronic infection.
Discussion
We present the first mathematical model of virus dynamics that
groups the different subpopulations of HIV-1-infected cells
according to their transcriptional profile. The model assumes a
heterogeneous population of latently and persistently infected cells
having occasional transcriptional bursts to increase their level of
RNA transcription which is consistent with experimental data
from Fischer et al. [12]. Fitting this model to the unique data of
virus transcription levels at the single cell level resulted in new
estimates of the HIV-1 dynamics in vivo. We found that a large
fraction of infected cells become either defectively or persistently
infected cells. Furthermore, we found that the viral burst size can
be high, between 3:5|103 and 2:4|105 viral particles per virus-
producing cell. Lastly, we simulated the acute phase of HIV-1
infection in a typical patient. This illustrated that the latently
infected cell pool becomes rapidly established during the first
months of acute infection and shows a slow increase during the
first years of chronic infection.
Our study is unique in that we fit a mathematical model of
HIV-1 within a host to data of the dynamics of different subclasses
of infected cells. This is a substantial step beyond modeling studies
that considered free virus in plasma, CD4z T cells and bulk
measurements of viral activity only. The new quantitative insights
Figure 3. Model of HIV-1 dynamics. Actively infected cells move through an intracellular eclipse phase (I1 to I5) before they start to produce virus
particles (I6). Some of the cells during the intracellular eclipse phase become either defectively infected (D), latently infected (L1) or persistently
infected (M1). Both latently (L1 and L2) and persistently (M1 andM2) can move between two transcriptional states. Persistently infected cells that are
in a high transcriptional state (M2) also contribute to virus production. The different subpopulations of infected cells can be stratified according to
their HIV-1 DNA and RNA content (shown on top).
doi:10.1371/journal.pcbi.1003871.g003
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into the replication dynamics of HIV-1 in vivo that this study
provides will be useful for an improved understanding of HIV and
the effects of novel treatment strategies.
The measurements of HIV-1-infected cells and the virus
concentration were performed in blood only. In our mathematical
model, we thus assume homogeneous mixing of virus and cells
throughout the body. It is important to note, however, that the
characteristic decay profile in the study by Fischer et al. [12] could
also be a result of differential trafficking of virus particles and HIV-
1-infected subpopulations of cells between the blood and lymphoid
tissue. It has also been suggested that the virion clearance rate
from the blood corresponds to a virion efflux to other organs
where the virus is ultimately cleared [34]. Furthermore, non-
productively infected CD4z T cells could also indirectly die
through ‘bystander’ effects [35,36]. Finally, the typical second-
phase decay could also result from virus production in infected
macrophages [20] or heterogeneity in activation rates of latently
infected cells [30,37].
The concept of persistently infected cells has been previously
used in mathematical models of HIV-1 dynamics to describe a
population of long-lived cells that can contribute to the second-
phase decay of virus during cART [20,26]. Since the cellular
subclass with medium transcriptional activity (Mid) seems to be
rather long-lived and strongly characterized by a decay dynamics
that could contribute to the second-phase decay of virus, we
assumed that the majority of persistently infected cells belong to
this class. This is consistent with the notion that persistently
infected cells could be in a lower state of activation [21]. The
contribution of other subpopulations of cells to the subclass Mid is
small as the average lifespan of those cells is longer (L2) or shorter
(I4) than that of persistently infected cells. It remains to be
determined whether persistently infected cells could indeed release
viral particles as a result of an increase in their transcriptional
level. However, the reversion of virus-producing cells into a lower
state of activation has been proposed previously [30]. The data did
not allow estimation of both the frequency and duration of
transcriptional bursts that lead to the release of virions in
persistently infected cells. We assumed that once persistently
infected cells release viral particles, the probability to die through
cell lysis is the same as the probability of reversion.
For simplicity, we considered only one type of CD4z target cell
whereas HIV-1 can infect activated but also resting CD4z T cells.
Our estimate of the proportion of CD4z T cells that are target
cells (1.1%) is somewhat lower than the 6.5% of CD4z Ki-67z T
cells in HIV-1-infected individuals that have been measured
previously [38]. Also, the estimated average lifespan of target cells
was longer than what others have estimated for activated cells
[39]. The target cells in the model thus represent a particular
subset of CD4z T cells that is smaller than the population of
activated cells but has a longer average lifespan. The longer
lifespan of target cells results from the assumption that the death
rates of cells during the intracellular eclipse phase (I1 to I5) and
Figure 4. HIV-1 dynamics during cART. Circles denote measured data of patient 112 and lines represent the best fit of the default model. Model
fits to data of the four other patients are given in Text S1.
doi:10.1371/journal.pcbi.1003871.g004
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persistently infected cells (P1) remain the same after infection, i.e.,
are the same as the death rate of uninfected target cells (T ). While
persistently infected cells are indeed defined as long-lived cells that
can produce virus, some studies have suggested that infected cells
in the eclipse phase could also be a target of cytotoxic T
lymphocyte (CTL) killing and experience high death rates [25,40–
42]. The early steps of proviral transcription also remain elusive. It
has been suggested that the decay of non-integrated viral DNA in
infected cells could render them CD4z target cells again [43–46].
The kinetics of HIV-1 DNA indeed show a small drop early after
start of cART (Figure 2 and ref. [47]). However, we have excluded
this effect for simplicity. Ultimately, the mechanisms of viral
latency in HIV-1 remain a matter of debate [48].
In our model, we assumed that after proviral insertion some
cells fail to increase viral RNA transcription and become latently
infected cells. Latency could also result from infection of resting
CD4z T cells or de-activation of activated CD4z T cells. We
have not included the latter two mechanisms in our model as the
data would not allow us to distinguish between them.
The complexity of the HIV-1 life cycle and its mathematical
representation prevents the identification of a ‘true’ underlying model.
We made several simplifying assumptions in our default model but we
also studied a series of alternative models and found that some of those
models also fit the data well (Table S1 in Text S1). Importantly, the
estimates of critical parameters such as the viral burst size, the
proportion of CD4z T cells that are target cells, and the fractions of
cells that become defectively, latently or persistently infected in the
alternative models that fit the data well were very similar to those
estimated with the default model (Table S2 in Text S1).
We were also able to reject some competing hypotheses about
the life cycle of HIV-1 (Table S1 in Text S1). Removing the
intracellular eclipse phase, that contains infected cells at different
stages with increasing levels of viral transcription, impairs the
model fit. Assuming that latently or persistently infected cells are
homogeneous subpopulations results in a substantially worse fit to
the data. The limited number of data points and patients
prevented a more thorough analysis and resulted in substantial
uncertainty in estimating the model parameters. The wide ranges
of estimates in Table 1 illustrate that the reported parameter
values need to be treated with caution. We also used the least-
squares method to fit the model to the data and did not consider
maximum likelihood approaches [49], values below the limit of
detection or nonlinear mixed-effect models [50].
It remains to be determined how well the parameter estimates
that were obtained during the chronic phase of infection represent
the situation of acute HIV-1 infection. It is re-assuring that the
simulated virus dynamics of acute infection show a peak around
three weeks after infection, which is in agreement with observa-
tions in patients [51,52]. Nevertheless, differences in immune
activation during acute infection are likely to result in different
proportions of cells becoming latent upon infection and different
activation rates of latently infected cells. Hence, our results on the
development of the latently infected cell pool during acute
infection need to be interpreted with caution.
We found the HIV-1 burst size in vivo to be large,
corroborating previous estimates from Chen et al. [53] who found
the average burst size in SIV-infected rhesus macaques to be
between 4:0|104 and 5:5|104. This is higher than other
Figure 5. Dynamics of HIV-1-infected subpopulations during cART. The 12 different cellular subpopulations from Figure 3 (patient 112) are
shown together with the virus. CD4z target cells (T ): black dashed line; actively infected cells during the intracellular eclipse phase (I1 to I5): blue
dashed lines; activated, virus-producing cells (I6): blue solid line; defectively infected cells (D): chocolate line; latently infected cells (L1 and L2): red
dashed and solid line, respectively; persistently infected cells (M1 and M2): green dashed and solid line, respectively; virus particles (V ): black solid
line. The dynamics of the cellular subpopulations for all other patients are given in Text S1.
doi:10.1371/journal.pcbi.1003871.g005
Quantifying the Turnover of HIV-1-Infected Cells
PLOS Computational Biology | www.ploscompbiol.org 6 October 2014 | Volume 10 | Issue 10 | e1003871
estimates that were in the range of 103 virions per cell [54,55] and
suggests that the number of virus-producing cells must be lower
than previously anticipated. Measurements of extracellular virion-
enclosed HIV-1 RNA (Extra) in the study by Fischer et al. [12]
suggest that the number of productively infected cells in peripheral
blood is small which is also reflected in our model fits. In contrast
to other studies that assumed the viral production rate in long-
lived persistently infected cells to be lower than in activated, virus-
producing cells [56], we considered the viral production rates to be
the same in both cell types. However, in our model persistently
infected cells can have occasional transcriptional bursts from Mid
to High, where they can release virus particles before reverting
back to a lower transcriptional state or dying.
Our simulations of the development of different pools of HIV-1-
infected cells are in good agreement with observations in patients.
We find that the total number of HIV-1 DNA positive cells rapidly
build up during the acute stage of infection. A very similar
expansion was found in a recent study that measured the total
number of HIV proviruses in PBMCs during the first weeks of
HIV infection [57]. Also, our predicted ratio of the number of
HIV-1 DNA positive cells during acute and chronic infection is in
the same range as previously reported [33,47]. The study by
Murray et al. [47] further suggested that the level of HIV DNA
continuously increases with duration of infection, reaching its 50%
level at two years after infection. This contradicts earlier findings
of stable levels of HIV-1 DNA positive PBMCs during the natural
course of infection [58]. Our model predicts that the number of
HIV-1 DNA positive PBMCs increases slowly during the first
years of chronic infection and reaches its 50% level at 451 days
after infection, corroborating the findings by Murray et al. [47].
An important question that remains is how many of HIV-1
DNA positive cells are latently or defectively infected. We found
that the fraction of cells becoming defectively infected is
surprisingly high. On the one hand, this could be a result of the
Table 1. Estimated parameters of HIV-1 dynamics.
Parameter Explanation and reference Constraint Estimate (average) Estimate (range) Unit
s Proportion of CD4z T cells
that are target cells
0:1%{10% 1:1% 0:2%{7:0% –
l Production rate of target cells 10{104 68:4 22:1{191:5 cells ml{1 d{1
E Drug effectiveness [23] 85% – – –
b Infection rate 10{8{10{4 1:4|10{6 4:0|10{7{1:4|10{5 ml virion{1 d{1
dT Death rate of target cells and
other infected cells
10{4{1 0:017 0:002{0:087 d{1
dD Death rate of defectively and
latently infected cells
(dD~dL1~dL2 )
10{6{0:1 8:3|10{5 5:4|10{6{5:9|10{3 d{1
dI6 Death rate of virus-producing
cells (dI6~dM2 ) [72]
1:0 – – d{1
c Clearance rate of free virus
particles [17]
23:0 – – d{1
fD Fraction of I2 that become
defectively infected cells
1%{99% 14:1% 3:5%{49:0% –
fL Fraction of I3 that become
latently infected cells
0:01%{10% 0:4% 0:2%{11:1% –
fM Fraction of I4 that become
persistently infected cells
0:1%{99% 25:0% 2:3%{93:3% –
c1 Transition rate from I1 to I2 [27] 3:0 – – d
{1
c2 Transition rate from I2 to I3 [27] 6:0 – – d
{1
c3 Transition rate from I3 to I4 [27] 12:0 – – d
{1
c4 Transition rate from I4 to I5 [27] 12:0 – – d
{1
c5 Transition rate from I5 to I6 [27] 12:0 – – d
{1
s1 Transition rate from L1 to L2 10{3{1:0 0:079 0:006{0:284 d{1
s2 Transition rate from L2 to L1
(assumption)
1:0 – – d{1
k1 Transition rate from M1 to M2 10{3{1:0 0:103 0:027{0:683 d{1
k2 Transition rate from M2 to M1
(assumption)
1:0 – – d{1
a Activation rate of latently
infected cells
10{6{0:1 2:7|10{3 5:3|10{5{1:5|10{1 d{1
N Viral burst size of virus-producing
cells infected cells
103{106 2:14|104 3:46|103{2:40|105 virions cell{1
Estimates are given as geometric means including the range over all five patients. Parameters without an estimate (–) were assumed to be fixed during the fitting
procedure. Intermediate values of the logarithmic range of constraint were used as starting values for the model fitting.
doi:10.1371/journal.pcbi.1003871.t001
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assumption that HIV-1 DNA positive cells without viral RNA
transcription remain silent. Some of these cells could actually be
activated and start to produce UsRNA at low levels, i.e., become
cells of the latent class L1. Eriksson et al. [59] measured a 300-fold
difference between the number of latently infected cells as
measured with a viral outgrowth assay and the total number of
HIV-1 DNA positive resting CD4z T cells. However, Ho et al.
[60] showed a substantial fraction of noninduced proviruses in
cells that have been stimulated in a viral outgrowth assay are
replication-competent. They found that that the frequency of
intact noninduced proviruses was at least 60-fold higher than the
frequency of proviruses induced in a viral outgrowth assay. The
median frequency of cells with intact non–induced proviruses per
HIV-1 DNA positive resting CD4z T cells was estimated at 3.7%
[60]. In our simulation, the fraction of latently infected cells
(L1zL2) in all HIV-1 DNA positive cells (DNAz) is 1.8% (140.4/
7608) during chronic infection. The striking correspondence of
these numbers suggests that our mathematical model realistically
describes the dynamics of the latent reservoir. Since the
subpopulation of L1 is much larger than L2, the majority of
latently infected cells consist of PBMCs that contain solely HIV-1
UsRNA (Low), indicating that this transcriptional subclass is a
good marker for viral latency.
This study provides an important step towards a more
quantitative understanding of the dynamics of HIV-1 in vivo, in
particular of the generation and maintenance of latently infected
cells. A better understanding of the number of latently infected
cells during acute infection is crucial for evaluating and predicting
the outcome of early treatment and eradication strategies. Early
cART treatment has been suggested to facilitate long-term control
of HIV-1 [61] and studies have shown that it results in lower viral
load levels during chronic infection [62]. Although the effects on
viral load might only be transient [63], early treatment can prevent
the expansion of viral cellular reservoirs in peripheral blood [33].
More recent strategies aim towards depletion of this reservoir [9],
preferably during acute infection [64]. Predicting the chances of
such eradication strategies critically depends on the ability to
accurately quantify the pool of latently infected cells at various
time points during HIV-1 infection. Our study supports the
experimental finding that the latent reservoir becomes rapidly
established during the first months of infection, and shows that the
reservoir represents a significant proportion (w1%) of all HIV-1
DNA positive PBMCs during chronic infection. In addition, our
mathematical model realistically describes the dynamics of
different HIV-1-infected subpopulations of cells which will be
useful for projecting the effects of eradication strategies.
Materials and Methods
Patient data
We used previously published data from five chronically HIV-1-
infected therapy naive patients that initiated cART using reverse
transcriptase and protease inhibitors (patient numbers: 103, 104,
110, 111, 112) [12]. Plasma HIV-1 RNA (copies per ml) and
CD4z T cells (per ml) were measured at several time points during
the first 48 weeks of cART. PBMCs were purified at weeks 0, 2, 4,
8, 12, 24 and 48 after the start of cART as described in Fischer et
al. [65]. Serial dilution of PBMCs and patient matched PCR
quantification of HIV-1 RNA species and DNA was performed as
described elsewhere in detail [12,13,66,67]. The freeze-thaw
nuclease digestion method to differentiate between intracellular
and virion encapsidated HIV-1 RNA has also been previously
described in detail [4,33]. HIV-1 RNA or DNA positive cell
fractions measured as cells per 106 PBMCs were converted to
number of cells per ml of blood by multiplying with the number of
PBMCs per ml. This ultimately lead to the stratification of cells to
five (partially overlapping) subclasses [12]:
N DNAz: PBMCs containing HIV-1 DNA
N Low: PBMCs containing solely HIV-1 UsRNA
N Mid: PBMCs containing only HIV-1 MsRNA-tatrev or
MsRNA-nef
N High: PBMCs containing elevated levels of both HIV-1
MsRNA-tatrev and MsRNA-nef
N Extra: PBMCs carrying virion-enclosed HIV-1 RNA
For the subclass DNAz, we make the assumption that there is
only one proviral DNA copy per infected cell [68].
Mathematical model
We devised a new virus dynamics model (Figure 3) which is
adapted from previously published models [19,25,26,30]. The
various subpopulations of infected cells were stratified according to
their HIV-1 DNA and RNA content. The model can be described
by the following set of ordinary differential equations (ODEs):
dT
dt
~l{(1{E)bVT{dTT , ð1Þ
dI1
dt
~(1{E)bVT{(c1zdI1 )I1, ð2Þ
dI2
dt
~c1I1{(c2zdI2 )I2, ð3Þ
Figure 6. Development of the latently infected cell pool during
acute and chronic of HIV-1 infection. The pool of latently infected
cells (L1+L2) is shown as a red line, the number of HIV-1 DNA positive
cells as a blue dash-dotted line and the plasma HIV-1 RNA as a black
dashed line. The average parameter estimates from Table 1 were used
for the model simulation. The gray areas represent two standard
deviations around the mean of the number of HIV-1 DNA positive cells
in patients that initiated cART during acute and chronic infection [33]
(for details, see Text S1).
doi:10.1371/journal.pcbi.1003871.g006
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dI3
dt
~(1{fD)c2I2{(c3zdI3 )I3, ð4Þ
dI4
dt
~(1{fL)c3I3zaL2{(c4zdI4 )I4, ð5Þ
dI5
dt
~(1{fM )c4I4{(c5zdI5 )I5, ð6Þ
dI6
dt
~c5I5{dI6I6, ð7Þ
dM1
dt
~fMc4I4zk2M2{(k1zdM1 )M1, ð8Þ
dM2
dt
~k1M1{(k2zdM2 )M2, ð9Þ
dL1
dt
~fLc3I3zs2L2{(s1zdL1 )L1, ð10Þ
dL2
dt
~s1L1{(azs2zdL2 )L2, ð11Þ
dD
dt
~fDc2I2{dDD, ð12Þ
dV
dt
~NdI6I6zqM2{cV : ð13Þ
CD4z target cells, T , are produced at rate l and can become
infected by virus particles, V , at rate b. E denotes treatment efficacy,
where E~0 before the start of antiretroviral therapy. Newly infected
cells move through the intracellular eclipse phase, where I1 denotes
the stage of reverse transcription, I2 the stage of proviral integration,
and I3 to I5 subsequent stages with increasing transcriptional activity.
After the intracellular eclipse phase, activated, virus-producing cells,
I6, start to release free virus particles with a total viral burst size N.
Some of the cells during the intracellular eclipse phase can become
defectively infected cells, D, latently infected cells, L1, or persistently
infected cells, M1. While we assume that defectively infected cells
remain transcriptionally silent, both latently and persistently infected
cells can exhibit transcriptional bursts that rise their transcriptional
profile from Low to Mid and Mid to High, respectively. Latently
infected cells in an elevated transcriptional state L2 can become
activated at rate a or move back to the lower transcriptional state L1.
Similarly, persistently infected cells that are highly transcriptionally
activeM2 can release free virus particles at rate q before they revert to
a state of lower transcriptional activity or die. di and c describe cell
death and viral clearance rates, respectively.
Due to the complexity of the full model, we make a number of
simplifying assumptions. First, we assumed several of the cell death
rates to be the same: the death rates of virus-producing cells
dM2~dI6 and the death rates of defectively and latently infected
cells dD~dL1~dL2 . The death rates of infected cells that are not
virus-producing and do not solely belong to a resting phenotype,
such as defectively and latently infected, were kept the same as the
death rate of target cells (dI1~dI2~dI3~dI4~dI5~dM1~dT ).
Second, the viral production rates in both virus-producing cells (I6
and M2) are kept the same, i.e., NdI6~q. Note, however, that
persistently infected cells (M2) have a lower burst size than
activated, virus-producing cells (I6) because they can revert to a
non-productive state (M1). The default model described above is
compared to a number of alternative models with different
assumptions of the viral life cycle (Text S1).
Model fitting
The default model contains 22 parameters of which 10 are fixed
to previously used values from the literature or based on
assumptions (Table 1). The remaining 12 parameters were
constrained based on literature values and consensus and we used
the geometric mean of the restricted range as starting values when
fitting the model to data. This proved to be a good strategy for
estimating the model parameters. The set of ODEs were solved
numerically in the R software environment for statistical
computing [69] using the function ode from the package deSolve
[70]. The 12 model variables were initiated with the target cells at
their steady-state (T(0)~l=dT ), V (0)~1 copy per ml, and all
other variables being zero. We assumed that the chronic state of
infection is reached after 1000 days (about three years), set E~0:85
[23] and further integrated the system during the time on cART
(336 days).
The concentration of free virus V was measured directly but several
of the infected cell populations contribute to the different subclasses of
PBMCs (Figure 3): DNAz~I2zI3zI4zI5zI6zM1zM2z
L1zL2zD, Low~I1zI3zL1, Mid~I4zL2zM1, High~
I5zI6zM2 and Extra~I6zM2. We further assume that target
cells, T , correspond to a fraction, s, of all CD4z T cells. All 12
parameters (11 model parameters and one scaling parameter) were
estimated by fitting the model to the data of each patient
individually and minimizing the sum of squared residuals (SSR)
between the prediction of the model and the data (taking the natural
logarithm). All data points were weighted equally. However, the
higher number of data points for free virus compared to cellular
subclasses (e.g., Extra) forced the model to fit the virus concentra-
tion better than the other variables. We used the minimization
algorithm by Nelder & Mead [71] that is implemented in the
function optim and the parallel package for parallel computation.
The algorithm by Nelder & Mead is very robust in finding local
optima. As a sensitivity analysis, we used different starting values for
the parameters and the method SANN that is a variant of simulated
annealing. Simulated annealing usually performs better in finding
global optima but is relatively slow. In both cases, we found the best-
fit parameter estimates to be the same or very similar to our default
fitting strategy. Parameter estimates are presented as geometric
means including the ranges over all five patients. Code files can be
obtained freely upon request from the corresponding author.
Supporting Information
Text S1 This file contains the calculation of the proportion of
cell types, the definition and results of the alternative models, the
fits of the default model to the data from the four other patients,
and the calculation of HIV-1 DNA positive cells from the study by
Schmid et al. [33].
(PDF)
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